BioSpace News Archive

ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.

- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for TARA-002 in Lymphatic Malformations - - On Track to Complete GMP Scale up and Comparability in 2H, 2021 - - Strong Cash Position of $169M as of December 31, 2020 -

In an ongoing effort to expand access to COVID-19 vaccines and help the country move forward from the pandemic, CVS Health announced that it will begin to administer vaccines to eligible populations on Sunday, March 14 at seven select CVS Pharmacy locations across Illinois.

-- Benchmark report marks beginning of increased focus on sustainability issues, in recognition of their impact on its business and patient health --

Nuvo Pharmaceuticals® Inc. d/b/a Miravo Healthcare, a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, announced Jesse Ledger, Miravo’s President & Chief Executive Officer and Kelly Demerino, Miravo’s Interim Chief Financial Officer will be presenting at the Q1 Virtual Investor Summit.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will host a webinar on its recently announced alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it expects to report its topline results for the Phase 2b part of its Phase 2b/3 COVID-19 trial of Ifenprodil, in the last week of March 2021.

Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today that it will release fiscal fourth quarter and full year financial results on Tuesday, March 30, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will present at the Oppenheimer 31 st Annual Healthcare Conference, a virtual event, on Wednesday, March 17, 2021 at 1:10 p.m. ET.